Pharmaceutical companies who make qualifying medicines can now take advantage of a streamlined approvals pathway for medicines much earlier than anticipated.

The Medicines and Healthcare products Regulatory Agency (MHRA) and National Institute for Health and Care Excellence (NICE) are now offering some pharmaceutical companies early access to the aligned pathway six months earlier than projected, as user research begins to shape the next phase of the programme. The pathway is now accepting applications from manufacturers who make medicines which have been designated by the NICE and the MHRA for early access.

The aligned pathway delivers on government ambitions in the Regulatory Action Plan, 10-Year Health Plan for England and the Life Sciences Sector Plan by streamlining regulation, acce

See Full Page